COVID-19与H1N1所致ARDS住院患者的比较
该回顾性病例对照研究比较了COVID-19(n=73)与H1N1(n=75)所致ARDS住院患者的临床表现、影像、治疗和预后。COVID-19组年龄更高,H1N1组男性比例更高;COVID-19组干咳、乏力、消化道症状比例更高,H1N1组SOFA评分更高。COVID-19组PaO2/FiO2为198.5 mm Hg,显著高于H1N1组的107.0 mm Hg(P<.001);COVID-19组磨玻璃影更常见(P<.001)。两组院内死亡率分别为28.8%和34.7%(P=.483),但H1N1组SOFA评分校正后死亡率显著高于COVID-19组,率比为2.009(95%CI 1.563-2.583;P<.001)。
要点
- H1N1相关ARDS患者SOFA评分校正后死亡率显著高于COVID-19相关ARDS患者,率比2.009(95%CI 1.563-2.583;P<.001)。
- COVID-19相关ARDS患者PaO2/FiO2为198.5 mm Hg,显著高于H1N1相关ARDS患者的107.0 mm Hg(P<.001)。
- H1N1相关ARDS患者SOFA评分高于COVID-19相关ARDS患者(P<.05)。
- COVID-19相关ARDS患者干咳、乏力、消化道症状比例高于H1N1相关ARDS患者(P<.05)。
- 两组院内死亡率分别为28.8%和34.7%,差异无统计学显著(P=.483)。
适用人群与场景
- 因COVID-19或H1N1感染导致ARDS的住院患者(COVID-19组n=73,H1N1组n=75)。
研究设计与关键结果
- 研究类型为回顾性病例对照研究,比较COVID-19相关ARDS(n=73)与H1N1相关ARDS(n=75)两个独立队列。
- COVID-19组中位年龄高于H1N1组,H1N1组男性比例更高(P<.05)。
- COVID-19组干咳、乏力、消化道症状比例高于H1N1组(P<.05);H1N1组SOFA评分高于COVID-19组(P<.05)。
- COVID-19组PaO2/FiO2为198.5 mm Hg,显著高于H1N1组的107.0 mm Hg(P<.001);COVID-19组磨玻璃影更常见(P<.001)。
- COVID-19组接受抗病毒治疗种类多于H1N1组。
- COVID-19组院内死亡率为28.8%,H1N1组为34.7%(P=.483)。
- H1N1组SOFA评分校正后死亡率显著高于COVID-19组,率比2.009(95%CI 1.563-2.583;P<.001)。
证据类型、等级与局限
- 证据类型:回顾性病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,COVID-19相关ARDS与H1N1相关ARDS在临床表现上存在诸多差异;与H1N1患者相比,COVID-19所致ARDS患者就诊时疾病严重程度评分较低,SOFA评分校正后死亡率较低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Since the outbreak of coronavirus disease 2019 (COVID-19) in China in December 2019, considerable attention has been focused on its elucidation. However, it is also important for clinicians and epidemiologists to differentiate COVID-19 from other respiratory infectious diseases such as influenza viruses.
RESEARCH QUESTION: The aim of this study was to explore the different clinical presentations between COVID-19 and influenza A (H1N1) pneumonia in patients with ARDS.
STUDY DESIGN AND METHODS: This analysis was a retrospective case-control study. Two independent cohorts of patients with ARDS infected with either COVID-19 (n = 73) or H1N1 (n = 75) were compared. Their clinical manifestations, imaging characteristics, treatments, and prognosis were analyzed and compared.
RESULTS: The median age of patients with COVID-19 was higher than that of patients with H1N1, and there was a higher proportion of male subjects among the H1N1 cohort (P < .05). Patients with COVID-19 exhibited higher proportions of nonproductive coughs, fatigue, and GI symptoms than those of patients with H1N1 (P < .05). Patients with H1N1 had higher Sequential Organ Failure Assessment (SOFA) scores than patients with COVID-19 (P < .05). The Pao2/Fio2 of 198.5 mm Hg in the COVID-19 cohort was significantly higher than the Pao2/Fio2 of 107.0 mm Hg in the H1N1 cohort (P < .001). Ground-glass opacities was more common in patients with COVID-19 than in patients with H1N1 (P < .001). There was a greater variety of antiviral therapies administered to COVID-19 patients than to H1N1 patients. The in-hospital mortality of patients with COVID-19 was 28.8%, whereas that of patients with H1N1 was 34.7% (P = .483). SOFA score-adjusted mortality of H1N1 patients was significantly higher than that of COVID-19 patients, with a rate ratio of 2.009 (95% CI, 1.563-2.583; P < .001).
INTERPRETATION: There were many differences in clinical presentations between patients with ARDS infected with either COVID-19 or H1N1. Compared with H1N1 patients, patients with COVID-19-induced ARDS had lower severity of illness scores at presentation and lower SOFA score-adjusted mortality.
参考来源
- Tang X, Du RH, Wang R, et al. Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1. Chest. 2020. PMID: 32224074. doi:10.1016/j.chest.2020.03.032
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。